🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhanjiang
Clinical trial register · China

Clinical Trials in Zhanjiang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University12 Merck Sharp & Dohme LLC6 Affiliated Hospital of Guangdong Medical University4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.4 Hoffmann-La Roche2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Zhanjiang

49 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study on the Efficacy and Safety of Anrikefon for Postoperative Pain Relief Following Laparoscopic Cholecystectomy
NCT07741188Gallbladder Stones, Gallbladder Polyps
Affiliated Hospital of Guangdong Medical University
Phase 2
144
Zhanjiang
2026-09-01
Not yet open
A Study of Combination Therapy in Patients With Resectable Liver Cancer
NCT07684040Liver Cancer (Primary and Metastatic)
Affiliated Hospital of Guangdong Medical University
Phase 2
68
Zhanjiang
2026-08-01
Not yet open
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
NCT07569757Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
260
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Zhanjiang, Nanning
2026-06
Not yet open
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
NCT07589049Head and Neck Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Qingyuan, Shantou, Shenzhen, Zhanjiang, Ganzhou
2026-05
By invitation
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
NCT07618624Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2026-04-20
Recruiting
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
NCT07390123IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
370
Huangshan City, Wuhu, Beijing, Zhanjiang, Changsha, Changchun, Linyi, Shanghai
2026-04-07
Recruiting
FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis
NCT07464392Acute Pancreatitis
Changhai Hospital
Not applicable
150
Fuzhou, Quanzhou, Guangzhou, Qingyuan, Zhanjiang, Shanghai
2026-04-02
Recruiting
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
NCT06768931Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy
Sun Yat-sen University
Phase 2
192
Lanzhou, Dongguan, Guangzhou, Zhanjiang, Zigong
2026-04-01
Recruiting
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
NCT07477626Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
Sun Yat-sen University
Phase 3
372
Dongguan, Guangzhou, Zhanjiang, Zhengzhou, Chengdu, Hangzhou, Beijing, Shanghai
2026-03-20
Recruiting
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
NCT07362979Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
243
Dongguan, Guangzhou, Shenzhen, Zhanjiang
2026-03-12
Recruiting
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
NCT07400523Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
446
Zhanjiang, Guangzhou, Shantou
2026-02-10
Recruiting
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
NCT07282353Primary Biliary Cholangitis
Cascade Pharmaceuticals, Inc
Phase 3
135
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhanjiang, Nanning
2025-12-01
Active, closed
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
NCT07201337Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
700
Dongguan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2025-11-17
Active, closed
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
NCT07245407Non-cystic Fibrosis Bronchiectasis
AstraZeneca
Observational
251
Beijing, Chongqing, Quanzhou, Lanzhou, Shenzhen, Zhanjiang, Nanning, Guiyang
2025-10-27
Not yet open
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
NCT07083739Primary Immune Thrombocytopenia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
320
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-08
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
1,123
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2025-05-22
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
NCT06862869Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Observational
800
Zhanjiang, Guangzhou, Kaifeng, Zhengzhou, Ürümqi, Beijing, Changsha, Changzhou
2025-04-30
Recruiting
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
NCT06900920Primary Immune Thrombocytopenia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
199
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-04-30
Recruiting
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
NCT06925464T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital
Phase 1/2
36
Beijing, Zhanjiang, Shanghai
2025-04-01
Recruiting
Effects of Vitamin D and Prebiotic Supplementation on Glucose Control During Pregnancy
NCT06553729Glucose Intolerance During Pregnancy
Huazhong University of Science and Technology
Not applicable
500
Zhanjiang, Wuhan
2025-02-24
Active, closed
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06712888Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
NCT07141056HCC - Hepatocellular Carcinoma, Psychological Distress, Immune Checkpoint Inhibitors (ICIs), Cancer, Treatment-Related
Guilin Medical University, China
Observational
700
Zhanjiang, Guilin, Shaoyang
2025-01-01
Recruiting
A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
NCT07251309Hyperkalemia
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
420
Bengbu, Wuhu, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhanjiang, Huizhou
2024-12-23
Recruiting
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
NCT06760273Bronchiectasis Adult
Shanghai Pulmonary Hospital, Shanghai, China
Observational
364
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning
2024-10-16
Recruiting
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
NCT06451861Acute Myeloid Leukemia
Guangdong Provincial People's Hospital
Phase 2
240
Dongguan, Foshan, Guangzhou, Shenzhen, Zhanjiang, Zhuhai, Haikou
2024-08-21
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
Merck Sharp & Dohme LLC
Phase 3
686
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Nanning
2024-07-24
Recruiting
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
NCT06319456CLL/SLL
Ascentage Pharma Group Inc.
Phase 3
344
Bengbu, Guangzhou, Zhanjiang, Zhengzhou, Wuhan, Changsha, Shanghai, Tianjin
2024-04-07
Recruiting
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
522
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang
2024-03-28
Recruiting
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
By invitation
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
NCT06169579Advanced Solid Tumor
Shenzhen NewDEL Biotech, Co., Ltd
Phase 1
96
Xiamen, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Wu’an
2024-02-04
Recruiting
Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study
NCT06194968Acute Ischemic Stroke
The First Affiliated Hospital of Zhengzhou University
Observational
1,800
Lanzhou, Zhanjiang, Beiliu, Guidong, Wuzhou, Yulin, Sanya, Jiamusi
2023-12-30
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Shijiazhuang, Harbin
2023-12-15
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning
2023-12-06
Recruiting
Comparison of a Single Versus Double Perclose Technique for TAVR
NCT06173115Severe Aortic Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
876
Bengbu, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Yulin, Changshacun, Zhengzhou
2023-10-20
By invitation
Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma
NCT06076252Ampullary Cancer, Bile Duct Cancer, Pancreas Cancer, Duodenum Cancer
Affiliated Hospital of Guangdong Medical University
Not applicable
150
Zhanjiang
2023-07-01
Active, closed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642Chronic Obstructive Pulmonary Disease (COPD)
Hoffmann-La Roche
Phase 3
1,290
Guangzhou, Zhanjiang, Zunyi, Lianyungang, Beijing, Changchun, Changsha, Chengdu
2022-12-29
Active, closed
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
NCT05535933Warm Antibody Autoimmune Hemolytic Anemia
Hutchmed
Phase 2/3
111
Fuyang, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Guilin, Haikou
2022-09-30
Recruiting
Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma
NCT07327216Nasopharyngeal Carcinoma (NPC)
Affiliated Hospital of Guangdong Medical University
Phase 3
180
Zhanjiang
2022-08-15
Active, closed
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
NCT05211232Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
450
Zhanjiang, Wuzhou, Guiyang, Changsha
2022-06-10
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
280
Hefei, Beijing, Chongqing, Fulingqu, Fuzhou, Guangzhou, Shantou, Zhanjiang
2022-02-03
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Merck Sharp & Dohme LLC
Phase 3
643
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Nanning, Haikou
2021-12-13
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Active, closed
Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine
NCT04946734PFO - Patent Foramen Ovale, Migraine
Guangdong Provincial People's Hospital
Phase 3
440
Xiamen, Guangzhou, Huizhou, Jiangmen, Shenzhen, Zhanjiang, Nanning, Shangqiu
2021-08-12
Active, closed
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations
NCT04695925Non-small Cell Carcinoma, EGFR Gene Mutation
Li Zhang, MD
Phase 3
294
Guangzhou, Zhanjiang
2021-03-29
Recruiting
Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction
NCT06069232Aortic Valve Disease
Sun Yat-sen University
Observational
2,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2021-03-01
Active, closed
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang
2019-10-02
Recruiting
Tricuspid RegurgitAtion rIsk modeL Study (TRAIL Study)
NCT06926959Tricuspid Regurgitation
Sun Yat-sen University
Observational
3,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2016-06-15
Recruiting
Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer
NCT02966483Rectal Neoplasms Malignant, Surgery
Sun Yat-sen University
Not applicable
1,114
Beijing, Chongqing, Guangzhou, Zhanjiang, Zunyi, Changsha, Hengyang, Changchun
2016-04
Rows per page Showing 1–49 of 49
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhanjiang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 49 of those studies with a site in Zhanjiang.

How many clinical trials are recruiting in Zhanjiang?

27 of the 49 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 14 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhanjiang), 49 studies
PhaseStudiesRecruitingShare
Phase 3261353.1%
Phase 28316.3%
Observational7614.3%
Not applicable5410.2%
Phase 1102%
Phase 1/2112%
Phase 2/3102%

Most active sponsors

Lead sponsors with the most studies (Zhanjiang)
Lead sponsorStudiesRecruiting
Sun Yat-sen University127
Merck Sharp & Dohme LLC62
Affiliated Hospital of Guangdong Medical University41
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.42
Guangdong Provincial People's Hospital21
Hoffmann-La Roche21
AbbVie11
Ascentage Pharma Group Inc.11
AstraZeneca10
Beijing GoBroad Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.